We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Launch of High-Quality Enzymes Suitable for Pre-Clinical and Process Development in mRNA Vaccine

Pyrophosphatase and T7 RNA Polymerase packets.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Takara Bio Europe (TBE) announced the launch of new High Quality (HQ) grade mRNA production enzymes "T7 RNA polymerase, HQ" and "Pyrophosphatase (inorganic), HQ" suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.

HQ grade enzymes have features more similar to GMP grade quality (e.g. the same set of quality tests as GMP grade, see details below) than RUO grade enzymes, facilitating a smooth transition to GMP-grade manufacturing. Additionally, the high volume format (1 mL/tube) offers convenience for scaling up processes.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
We are expanding our lineup of HQ enzymes to support pre-clinical and process development stages in mRNA production, including another HQ grade product "Recombinant RNase Inhibitor, HQ", set to be launched soon. We also plan to sequentially provide GMP grade enzymes suitable for active pharmaceutical ingredients for manufacturing mRNA vaccines and therapeutic drugs.

GMP grade reagents are manufactured and quality controlled in accordance with the GMP guidelines of PIC/S (Pharmaceutical Inspection Agreement and Pharmaceutical Inspection Joint Scheme). GMP grade reagents are suitable for manufacturing active pharmaceutical ingredients for clinical trials.